ArticleBreast cancer research and treatment2018
Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis.BMJ open · 2021Pooled it
- Risk of Recurrence in Patients with HR+/HER2- Early Breast Cancer: A Podcast.Targeted oncology · 2026Article
- Case-mix-adjusted benchmarking of long-term breast cancer-specific mortality: Insights from a nationwide Swedish registry.Breast (Edinburgh, Scotland) · 2026Article
- The RESILIENT Study: A Retrospective, Descriptive, Correlational Investigation of Correlates of Oral Endocrine Therapy Adherence in Older Women With Breast Cancer.Cancer medicine · 2026Article
- Article
- Poor adherence to cancer therapy in Ethiopia: systematic review and meta-analysis.Public health reviews · 2026Review
- Impact of Side Effects on 5-Year Adherence to Adjuvant Endocrine Therapy in Women with Breast Cancer: An Integrative Review.International journal of women's health · 2026Review
- Side effects and adherence trajectories of adjuvant endocrine therapy in breast cancer patients: results from the VICAN2 study.Breast cancer research and treatment · 2025Article
- Adherence to oral anticancer medications in metastatic versus nonmetastatic breast cancer patients: Insights from a low-middle-income country.Exploratory research in clinical and social pharmacy · 2025Article
- Extended endocrine therapy use and decision making after breast cancer diagnosis.Journal of the National Cancer Institute · 2025Article
- Influencing Factors of Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients: A Meta-Analysis.Health science reports · 2025Review
- Clinical management of oligometastatic cancer: Applying multidisciplinary tumor board recommendations in practice.Clinical and translational radiation oncology · 2024Article
- Breast cancer survivors' opinion on personalizing endocrine therapy and developing informative tools.NPJ breast cancer · 2024Article
- Follow-up Routines Matter for Adherence to Endocrine Therapy in the Adjuvant Setting of Breast Cancer.Breast cancer : basic and clinical research · 2024Article
- Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App.JCO oncology practice · 2023Article
- Resistance to Resilience: Understanding Post-surgical Hormone Therapy in Breast Cancer Care.Cureus · 2023Review
- Social inequality in cancer survivorship: Educational differences in health-related quality of life among 27,857 cancer survivors in Denmark.Cancer medicine · 2023Article
- Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review.Journal of breast cancer · 2023Article
- Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.Breast cancer research and treatment · 2023Article
- The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa.Breast cancer research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeTo examine factors associated with non-adherence during 5 years of endocrine treatment, including the possible influence of comorbidity burden and specific medical conditions.
methodsFrom all women diagnosed with stage I-III, ER-positive breast cancer in Stockholm-Gotland, Uppsala-Örebro and Northern Sweden between 2006 and 2009, we included 4645 women who had at least one dispensation of tamoxifen or aromatase inhibitors (AIs) and 5 years of follow-up without distant recurrence. A medical possession ratio of < 80% was used to define non-adherence. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of non-adherence.
resultsDuring follow-up, 977 (21%) women became non-adherents. Non-adherence was associated with greater comorbidity burden assessed by Charlson comorbidity index (CCI) during follow-up (OR 1.43; 95% CI 1.08-1.88 for ≥ 2 additional scores compared to 0), pre-diagnostic HRT use (OR 1.99; 1.58-2.49), not married (OR 1.42; 1.23-1.64), high educational level (OR 1.25; 1.02-1.53 compared to lowest level), and use of symptom-relieving drugs. HER-2 positivity (OR 0.61; 0.45-0.81) and adjuvant chemotherapy (OR 0.42; 0.35-0.52) were associated with lower odds of non-adherence. Similar patterns were observed for the presence of lymph node metastasis, higher tumour grade, and use of AIs compared to tamoxifen. Myocardial infarction and chronic pulmonary disease was suggested as leading conditions associated with non-adherence in women with increasing CCI.
conclusionWe identified subgroups of women with breast cancer at increased risk of non-adherence. Our findings related to comorbidity suggest the importance of focusing on the presence of specific co-existing conditions when monitoring adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.